Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients
Inflammatory Bowel Disease, 04/05/2010Loftus EV et al.
Adalimumab was both effective and well tolerated for the treatment of CD in this tertiary practice with a high prevalence of past infliximab exposure. This experience largely predates FDA approval of adalimumab for CD.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.